UKAI Life Sciences Working Group
Helping senior life science leaders shape the future of AI in the pharmaceutical, biotechnology and medical devices industry.
The UKAI Life Science Working Group brings together senior leaders across pharmaceutical, biotechnology and medical devices industry coupled with a digital innovation to tackle the practical challenges of AI adoption in this particular sector. From the compliance and safety to automation, quality assurance, and patient trust, the group supports those leading transformation in a highly regulated and high-stake environment.
About the Group
The UKAI Life Sciences Working Group is shaping how the pharmaceutical, biotechnology and medical devices industry responds to the opportunities and risks of
AI adoption. From rethinking AI governance within this sector and regulatory compliance to enabling automation, compliance, and patient-centred innovation, the group supports senior leaders navigating challenges in this highly regulated sector.
Chaired by Natasha Mihajlovic, a leading expert in quality, compliance and digital transformation, the group meets quarterly and contributes to UKAI’s broader work across AI policy, governance, and sector-specific best practice. It plays a key role in ensuring our guidance, events and engagement reflect the real-world needs of those on the front line of AI in the life sciences.
The group is strategic and outcome-driven, creating space for the life science leaders to share insight, address operational challenges, and shape a responsible, forward-looking approach to AI adoption.
- Member-led roundtables and deep dives on AI use, challenges, risk, and impact on pharma, biotech and medical devices industry
- Development of practical AI guidance for this sector
- Cross-sector and cross-regulator AI policy engagement
- Thought leadership on AI governance, and data-driven innovation
Meetings are held under the Chatham House Rule and bring together a diverse mix of leaders from across pharma, biotech and medical devices industry, digital transformation, and compliance functions.
Meet the Group
Natasha Mihajlovic
Chair of the Pharma Working Group & Managing Director at NostraPharma
Natasha Mihajlovic is a highly respected quality, and compliance expert with over 28 years of experience spanning pharmacovigilance, regulatory compliance, and quality systems. She is the Managing Director of NostraPharma, where she advises global pharma and biotech companies on AI governance, compliance and auditing and the effective integration of AI within existing businesses. As Chair of the Life Sciences Working Group, she champions clear, proportionate compliance to support responsible AI adoption and UK innovation. Her leadership continues to shape the future of quality and compliance, with a focus on practical, AI governance solutions.
Get Involved
Golden Cross House
8 Duncannon Street
London WC2N 4JF
020 3488 3612
contact@ukai.co
